CDMOs & CROs

CDMOs, CROs and packaging service providers are under great pressure to adapt to new drug formats, formulations and automated preclinical test procedures, while at the same time facing a global shortage of qualified personnel. In addition to classic antibody and conjugate drugs and various RNA drugs and vaccines, cell and gene therapies that are increasingly complex to produce, the first in vivo CRISPR treatments or synthetic peptide hormone combinations – and, on the CRO side, cell- and organoid-based drug discovery technologies, new trial designs and AI – are entering the market. Become visible in European Biotechnology’s CDMO & CRO special and present your offer/portfolio to customers.

Present your expertise
CDMOs & CROs, providers of modular production plants, equipment, AI, and experts in emerging areas will have the opportunity to present their latest products, services, and equipment in this special. European Biotechnology goes out to decision makers throughout the entire European Life Science sectors. Take advantage of the journal’s highly relevant readership and grab this opportunity to target your audience!

Topics to be covered
CDMOs: Process development, automation, synbio, ATMPs, vector manufacturing, mRNA vaccines/therapeutics, ADCs, radio-conjugates, single use equipment, automated cell culture/sorting/seeding, media/cell line development, glyco-engineering, packaging, up- & downstream processing, fill & finish, QbD, combination
therapies.

CROs: Stratification, drug discovery services, CRISPR, immunooncology, biomarker/drug approval, biosimilars, animal/organoid models, microfluidics, ADMET, adaptive trails, EMR-guided patient recruitment, remote monitoring, AI tools, iPSC-based models.

Contact:
Editorial Contact: Thomas Gabrielczyk (t.gabrielczyk@biocom.de)
Marketing Contact: Oliver Schnell (o.schnell@biocom.de), Andreas Macht (a.macht@biocom.de)